Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

In July 2024, Sanders co-wrote an opinion piece with President Joe Biden—published in USA Today—taking aim at both Novo and ...

Jim Cramer warned that if the housing market rally keeps going, it might lead to a sell-off if the Federal Reserve announces ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Eli Lilly and Company ’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

One of the most prominent areas in the healthcare industry right now is weight loss. Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have witnessed ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the ...